Educational research & price index · Independent Janoshik & MZ Biolabs COA verification

HHS 503A peptide policy (Oct 30, 2026): the 6 peptides, explained

On October 30, 2026, HHS published a notice in the Federal Register (document 2026-22192) announcing an interim enforcement discretion policy for compounding six peptides under section 503A of the FD&C Act. Last verified against the Federal Register text on Nov 2, 2026.

What it is, and what it is not

The 6 peptides

PeptideDosage forms named by HHSResearch-vial $/mgCompound guide
BPC-157 (acetate)Subcutaneous, intramuscular, oral, topicalCompare $/mgGuide
TB-500 (acetate)Subcutaneous or intramuscular injectableCompare $/mgGuide
Epitalon (acetate)Subcutaneous or intramuscular, intermittent coursesCompare $/mgGuide
MOTS-cSee Appendix BCompare $/mgGuide
SemaxSee Appendix BCompare $/mgGuide
KPVSee Appendix BCompare $/mgGuide

$/mg tables list research-vial suppliers only, sorted strictly by price. For prescription routes, bloodwork labs and telehealth clinics are listed separately on Labs & Telehealth Clinics.

Free 1-page cheat sheet: U-100 reconstitution chart + weekly $/mg price drops.

Sources

Common questions

Which peptides are in the HHS 503A enforcement discretion policy?

BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV, per the HHS notice published in the Federal Register on October 30, 2026 (document 2026-22192).

Does this mean these peptides are FDA approved?

No. The notice states compounded drugs are not FDA-approved and that the interim policy is not binding and may be revisited.

Does the policy change research-use-only peptide vials?

No. It addresses compounding by State-licensed pharmacies, Federal facilities and licensed physicians under section 503A.

Educational summary, not legal or medical advice. Research-use-only products are not for human consumption.